Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Connie Collins"'
Autor:
Sunil Patel, Connie Collins, Nirmish Singla, Andrew Gabrielson, Trinity J. Bivalacqua, Noah Hahn, Max Kates
Publikováno v:
Journal of Urology. 207
Autor:
Sunil H. Patel, Andrew Gabrielson, Connie Collins, Nirmish Singla, Trinity Bivalacqua, Noah M. Hahn, Max R. Kates
Publikováno v:
Journal of Clinical Oncology. 41:507-507
507 Background: Combination intravesical Gemcitabine and Docetaxel (GEMDOCE) has demonstrated benefit for bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) in retrospective series and is now being widely utilized
Autor:
Sabine Ermisch, Ting Wang, Michael A. Carducci, Jeannette Day, Deborah K. Armstrong, Lori Kornberg, Rodney Decker, Connie Collins, Steven J. Nicol, Donald Thornton, Lee P. Resta, Zhe Zhang, Nwabundo Nwankwo
Publikováno v:
Investigational New Drugs
Summary Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination’s safety and efficacy. Patients and methods Six
Autor:
Connie Collins, Glenn Heller, Michael A. Carducci, Samuel R. Denmeade, Martin Fleisher, Roberto Pili, Dana E. Rathkopf, Mario A. Eisenberger, Tracy Curley, Moshe A. Kelsen, Howard I. Scher, Susan F. Slovin, Michael J. Morris, Sharyn D. Baker, Melinda Halter
Publikováno v:
Journal of Clinical Oncology. 26:2959-2965
Purpose We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers. Patients and Methods Noncastrate patients with ≤ 6 months of hormone therapy were eligible. Cohort 1 (62 patients) rece
Autor:
Connie Collins, Ming Zhao, Sharyn D. Baker, Ross C. Donehower, Michael A. Carducci, Wells A. Messersmith, Michelle A. Rudek, A. Dimitrios Colevas, Antonio C. Wolff
Publikováno v:
European Journal of Cancer. 43:78-86
A phase I study of Dimethylamino Benzoylphenylurea (BPU), a tubulin inhibitor, was performed using a weekly continuous schedule. Patients with refractory solid tumours received oral BPU once weekly without interruption at doses ranging from 5 to 320m
Autor:
Kampmeier, Connie Collins
Publikováno v:
Available to subscribers only..
Thesis (Ph.D.)--Southern Illinois University Carbondale, 2007.
"Department of Health Education and Recreation." Includes bibliographical references (p. 123-128). Also available online.
"Department of Health Education and Recreation." Includes bibliographical references (p. 123-128). Also available online.
Autor:
Michael A. Carducci, Roberto Pili, Connie Collins, Saby George, Li Shen, Hans J. Hammers, Anita Sandecki
Publikováno v:
Journal of Clinical Oncology. 31:369-369
369 Background: Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been shown to have anti-tumor activity in different malignancies and to induce immuno-modul
Autor:
Roberto Pili, Igor Espinoza-Delgado, Anita Sandecki, Michael A. Carducci, Hans J. Hammers, Connie Collins, Saby George, Li Shen
Publikováno v:
Journal of Clinical Oncology. 30:TPS4687-TPS4687
TPS4687 Background: Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been shown to have anti-tumor activity in different malignancies and to induce immuno-m
Autor:
Steven J. Nicol, Luna Musib, Ting Wang, S. Schaefer, Connie Collins, Michael A. Carducci, S. Ermisch, Deborah K. Armstrong, Zhen Zhang, Donald Thornton
Publikováno v:
Journal of Clinical Oncology. 27:3517-3517
3517 Background: ENZ, an oral kinase inhibitor, suppresses tumor growth through PKC and PI-3 kinase/AKT. BV binds VEGF and inhibits angiogenesis. Since ENZ and BV are complementary in inhibiting angiogenesis, we conducted a Phase I study of ENZ / BV.
Autor:
Ting Wang, Connie Collins, Zhe Zhang, Donald Thornton, S. Ermisch, Deborah K. Armstrong, L. P. Resta, Steven J. Nicol, Michael A. Carducci
Publikováno v:
Journal of Clinical Oncology. 26:3529-3529
3529 Background: ENZ is an oral kinase inhibitor that suppresses tumor growth through PKC and PI-3 kinase/AKT. BV is a monoclonal antibody that binds VEGF and inhibits angiogenesis. Since ENZ and B...